Ascendia

  MARKET NEWS

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish & Drug-Device Delivery Combination Capabilities
Cellares & Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
Argo Biopharma Announces First Subject Dosed in Phase I Study of siRNA Therapeutic BW-50218
Bio-Rad Launches PTC Harmony 96 & PTC Harmony Deepwell Thermal Cyclers
PTC Therapeutics to Report Results From PIVOT-HD Long-Term Extension Study
Evonik & Higuchi Strengthen Oral Drug Delivery Innovation in Japan With New Joint Laboratory
BD & Suttons Creek Partner to Help Pharma a& Biotech Companies Deliver Combination Products to Market With Confidence
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

  EXPERT CONTENT & RESOURCES

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.

On-Demand Presentation: Analytical Strategy & Challenges for ADC

On-Demand Presentation: Analytical Strategy & Challenges for ADC

Global Vice President of Analytical & Research Development, Scott Zugel, spoke at Veranova’s SCALE Symposium, where he outlined key analytical strategies and challenges in ADC manufacturing in the pharmaceutical industry.

Portrait of Bryn L. Dubin

America’s Next Healthcare Crisis Is Already Here - And We’re Not Ready

Bryn L. Dubin, Master’s Student at the LBJ School of Public Affairs studying health and economic policy. Dubin has federal and state legislative and policy analysis experience.

  FEATURED EDITORIAL

  COMPANY PROFILE

Bespak is a global Contract Development and Manufacturing Organisation (CDMO) solely focused on inhaled and nasal drug delivery. Headquartered in Holmes Chapel, UK, the company develops and manufactures inhaled and nasal drug products, drug delivery devices and components for the global pharmaceutical industry. Bespak provides a specialist, fully integrated service to support customers from early-stage feasibility, analytical and formulation development, product development and clinical supply, through to full-scale cGMP batch production. Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 6 – Nasal Delivery
May 13 – Capsules